BRIEF published on 08/12/2024 at 13:05, 1 year 3 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 3 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 4 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 4 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 5 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 5 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 5 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 12/05/2025 at 02:35, 7 hours 56 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 9 hours 31 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 26 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 31 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:15, 16 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 51 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 1 minute ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 26 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 31 minutes ago Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 08:45, 1 hour 46 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 31 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 46 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 47 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
